Hear from executive leaders who will discuss their ambitions, strategies and challenges for the future cell and gene therapies, the hottest indications of unmet need and progress towards the next commercial approval, which include:

• What are the future opportunities, promising targets and applications on the horizon for cell and gene therapies to achieve clinical success?
• What are the current industry’s top priorities and upcoming hurdles to development, such as investment, manufacturing, pricing and reimbursement and commercialization to better prepare and strategize to navigate the evolving landscape
• How to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your CAR-T, gene editing and therapeutic programs